Teuvo L.J. Tammela
A5011425417- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary Bladder and Prostate Research
- Cancer, Lipids, and Metabolism
- Hormonal and reproductive studies
- Pelvic floor disorders treatments
- Cancer-related molecular mechanisms research
- Bladder and Urothelial Cancer Treatments
- Genetic Associations and Epidemiology
- Urological Disorders and Treatments
- Urinary Tract Infections Management
- Molecular Biology Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Global Cancer Incidence and Screening
- Urologic and reproductive health conditions
- Bone health and treatments
- Lipoproteins and Cardiovascular Health
- Genetic factors in colorectal cancer
- Sexual function and dysfunction studies
- Nutrition, Genetics, and Disease
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Cancer-related gene regulation
- Genital Health and Disease
Tampere University
2016-2025
Tampere University Hospital
2016-2025
Lund University
2022
Helsinki University Hospital
2000-2017
Finnish Cancer Registry
2000-2017
University of Helsinki
2011-2017
Prostate Cancer Research
2017
Cancer Research Center
2017
Päijät-Hämeen Keskussairaala
2017
Uppsala University Hospital
2017
The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate effect screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer.We identified 182,000 men between ages 50 and 74 years through registries seven countries inclusion our study. were randomly assigned a group that offered PSA at an average once every 4 or control did not receive such screening. predefined core age this study included 162,243 55 69 years....
Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated in European Randomized Study Screening for Prostate Cancer with 2 additional years follow-up.
We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased for disease.
Androgen-deprivation therapy is well-established for treating prostate cancer but associated with bone loss and an increased risk of fracture. We investigated the effects denosumab, a fully human monoclonal antibody against receptor activator nuclear factor-κB ligand, on mineral density fractures in men receiving androgen-deprivation nonmetastatic cancer.
Abstract MicroRNAs (miRNA) are small, endogenously expressed noncoding RNAs that negatively regulate expression of protein-coding genes at the translational level. Accumulating evidence, such as aberrant miRNAs, suggests they involved in development cancer. They have been identified various tumor types, showing different sets miRNAs usually deregulated cancers. To identify miRNA signature specific for prostate cancer, profiling 6 cancer cell lines, 9 xenografts samples, 4 benign prostatic...
Darolutamide is a structurally unique androgen-receptor antagonist that under development for the treatment of prostate cancer. We evaluated efficacy darolutamide delaying metastasis and death in men with nonmetastatic, castration-resistant
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients nonmetastatic, castration-resistant prostate cancer. Whether combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase metastatic, hormone-sensitive cancer unknown.
PURPOSE: The combination of interferon alfa-2a (IFNα2a) plus vinblastine (VLB) induces objective tumor responses in patients with advanced renal cell cancer. However, no prospective randomized trial has shown that this treatment prolongs overall survival. We compared survival after IFNα2a VLB versus alone PATIENTS AND METHODS: prospectively 160 locally or metastatic cancer to receive either for 12 months until progression disease. In both groups, was administered intravenously at 0.1 mg/kg...
After 11 years of follow-up, the European Randomized Study Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening prostate-specific antigen (PSA) levels. However, extent to which harms quality life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain.